Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovac Depot SCIT in Rhinoconjunctivitis Sensitized to D. Pteronyssinus
NCT01564017Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- May 2012
- Primary completion
- May 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of allergovac depot in allergic rhinoconjunctivitis (ARC), sponsored by ROXALL Medizin GmbH. Started May 2012; status: completed.
02
Drugs
allergovac depot
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01564017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01564017.